![](https://monteverdelaw.com/wp-content/uploads/case-logo/trillium-therapeutics-inc.png)
Trillium Therapeutics, Inc. (TRIL) relating to its proposed acquisition by Pfizer, Inc. Under the terms of the agreement, TRIL shareholders will receive $18.50 in cash per share they own.
Trillium Therapeutics, Inc. (TRIL) relating to its proposed acquisition by Pfizer, Inc. Under the terms of the agreement, TRIL shareholders will receive $18.50 in cash per share they own.